Navigation Links
BioNumerik Commences Global Phase III Ovarian Cancer Trial on Novel Anticancer Drug Candidate Known as Karenitecin(R)
Date:2/7/2008

safety profile and fewer of the

dose-limiting side-effects caused by camptothecin drugs including:

- lower incidence of severe diarrhea than that caused by irinotecan

(also known as Camptosar(R));

- lower incidence of anemia and neutropenia (reduction in white blood

cell counts), than that caused by topotecan (also known as

Hycamtin(R));

-- Less susceptibility than currently marketed camptothecins to common

drug resistance mechanisms found in many types of human cancer cells,

including resistance mechanisms that are specific to the camptothecin

class; and

-- Because Karenitecin is lipophilic (fat loving), BioNumerik believes

Karenitecin may have enhanced tissue penetration, drug delivery and

bioavailability compared to existing water soluble camptothecins.

In commenting on these developments, Frederick H. Hausheer, M.D., BioNumerik's Chairman & Chief Executive Officer stated: "There is a large unmet need for 2nd and 3rd -line therapies that can prevent progression of recurrent or progressive ovarian cancer with reduced risk of cumulative toxicity in patients who have become resistant to platinum/taxane-based chemotherapy. Ovarian cancer is difficult to diagnose early and patients are usually diagnosed with advanced disease (Stage III or IV). Outcomes for patients with advanced ovarian cancer remain poor. Up to 80% of ovarian cancer patients who initially respond to treatment will ultimately relapse and require additional therapy, and treatment options for patients with advanced recurrent ovarian cancer are limited. In addition, all approved agents for the treatment of advanced ovarian cancer are associated with significant toxicity that can be dose-limiting."

Dr. Hausheer added, "We believe the safety and efficacy outcomes from the previously completed Karenitecin Phase II advanced ovarian cancer trial compare favorably with
'/>"/>

SOURCE BioNumerik Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. EntreMed Commences Phase 2 Study With MKC-1 in Ovarian/Endometrial Cancers
2. Nektar Commences Phase 2 Trial of NKTR-118 (oral PEG-naloxol) Evaluating Efficacy and Safety as Treatment for Opioid-Induced Bowel Dysfunction
3. Nektar Commences Phase 2 Clinical Development Program for NKTR-102 (PEG-Irinotecan) in Colorectal Cancer
4. Alexion Commences Dosing in AEGIS Registration Study of Soliris(R) (eculizumab) in Patients with PNH in Japan
5. EntreMed Commences Phase 2 Study with MKC-1 in Pancreatic Cancer
6. Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C
7. Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV
8. Sunesis Pharmaceuticals Commences Clinical Trials of SNS-595 and SNS-314
9. Sinovac Commences Vaccination on Volunteers for Phase II Clinical Trial on Pandemic Influenza H5N1 Vaccine
10. Memory Pharmaceuticals Commences Phase 1 Clinical Program for R4996/MEM 63908
11. Dr. Rajeev Venkayya Joins Gates Foundation as Director of Global Health Delivery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... YORK , August 21, 2014 ... Israeli subsidiary, BreedIT Ltd., the exclusive worldwide license ... software for plant breeders and researchers, today is ... a joint venture with Seach Ltd, a leading ... formed to research and develop new breeds of ...
(Date:8/21/2014)... 2014  ACI Clinical ( www.aciclinical.com ) announces ... Committees. Using this solution, trial sponsors ... standard costs and receive the same expertise that ... services. Leveraging a decade of DMC ... development, statistical programming and meeting facilitation), ACI analyzed ...
(Date:8/21/2014)...  Henry Schein, Inc. (NASDAQ: HSIC ), the ... office-based dental, animal health and medical practitioners, announced today that ... , September 4, 2014 – Baird 2014 Healthcare ... p.m. ET , September 8, 2014 – ... , NY at 1:25 p.m. ET Henry ...
Breaking Medicine Technology:BreedIT Ltd. and Seach Ltd. Form KanaboSeed to Develop New Medical Cannabis Varieties 2BreedIT Ltd. and Seach Ltd. Form KanaboSeed to Develop New Medical Cannabis Varieties 3BreedIT Ltd. and Seach Ltd. Form KanaboSeed to Develop New Medical Cannabis Varieties 4ACI Clinical: Innovation and Savings in Data Safety Monitoring Committees 2Henry Schein To Present At Two Investor Conferences In September 2
... Pharmaceuticals, Inc. (Nasdaq: TRBN ) today announced financial ... Sept. 30, 2009. , (Logo: http://www.newscom.com/cgi-bin/prnh/20090320/TRUBIONLOGO ) , ... , Revenue for the third quarter and ... and $12.8 million, respectively, compared with $3.8 million and ...
... SADDLE RIVER, N.J., Nov. 5 PDI, Inc. (Nasdaq: PDII), ... to U.S. pharmaceutical companies, today reported financial and operational results ... Commenting on today,s announcement, Nancy Lurker, Chief Executive Officer of ... were lower than last year by approximately 14%. Higher ...
Cached Medicine Technology:Trubion Pharmaceuticals, Inc. Reports Third Quarter and Nine Months 2009 Financial Results 2Trubion Pharmaceuticals, Inc. Reports Third Quarter and Nine Months 2009 Financial Results 3Trubion Pharmaceuticals, Inc. Reports Third Quarter and Nine Months 2009 Financial Results 4Trubion Pharmaceuticals, Inc. Reports Third Quarter and Nine Months 2009 Financial Results 5Trubion Pharmaceuticals, Inc. Reports Third Quarter and Nine Months 2009 Financial Results 6Trubion Pharmaceuticals, Inc. Reports Third Quarter and Nine Months 2009 Financial Results 7PDI Reports 2009 Third Quarter Financial Results 2PDI Reports 2009 Third Quarter Financial Results 3PDI Reports 2009 Third Quarter Financial Results 4PDI Reports 2009 Third Quarter Financial Results 5PDI Reports 2009 Third Quarter Financial Results 6PDI Reports 2009 Third Quarter Financial Results 7PDI Reports 2009 Third Quarter Financial Results 8PDI Reports 2009 Third Quarter Financial Results 9PDI Reports 2009 Third Quarter Financial Results 10PDI Reports 2009 Third Quarter Financial Results 11
(Date:8/21/2014)... According to a new market report published ... Industry Analysis, Size, Share, Growth, Trends and Forecast, 2012 ... at USD 236.1 million in 2011 and is estimated ... 2018 at a CAGR of 6.3% from 2012 to ... http://www.transparencymarketresearch.com/fundus-cameras.html . , Fundus cameras market growth in ...
(Date:8/21/2014)... 21, 2014 It's a terrible thing when ... to a serious substance abuse issue. When that happens to ... action is getting reliable help from the qualified substance abuse ... facility isn’t always easy for those young adults living in ... significant addiction issue. , Thankfully there is a new ...
(Date:8/21/2014)... The worlds of personal care and yoga are ... grab free products. BaliniSports will be shipping ... with all qualifying purchases for a limited time. “The ... apparel is simply perfect,” said Ada Hung, founder and ... brands is intended to give people in the yoga ...
(Date:8/21/2014)... Rockville, Maryland (PRWEB) August 21, 2014 ... developed with guidance from Lockton Companies and builds ... the industry’s only cellular glucometer, combined with Accountable ... and robust data analytic capabilities and adds a ... provider care, including eye exams, provider visits, HbA1c ...
(Date:8/21/2014)... Tibet has long been a desired ... kingdom. Prayers flags whip in the wind against ... rumble of chanting monks fill the otherwise silent temples. ... access to Tibet is challenging due to high elevation ... prove to be daunting for even the most experienced ...
Breaking Medicine News(10 mins):Health News:Fundus Cameras Market: Product Type- Mydriatic, Non-Mydriatic, Hybrid and ROP Cameras; End Users- Hospitals, Ophthalmology Clinics and Ophthalmic & Optometrist Offices 2Health News:Young Adults in Pompano Beach, FL Are Finding Success With Innovative New Helpline 2Health News:Tom's of Maine Partner up with BaliniSports Yoga Apparel 2Health News:Accountable Health Expands Diabetes Management Solutions to Address Gaps in Provider Care 2Health News:Accountable Health Expands Diabetes Management Solutions to Address Gaps in Provider Care 3
... HealthDay Reporter , MONDAY, Aug. 30 (HealthDay News) -- ... summer months, new research shows. In a study using ... from Brigham and Women,s Hospital in Boston found that new ... spring and summer compared to colder times of the year. ...
... women during visits to family planning clinics whether their ... a type of intimate-partner violence called reproductive coercion ... continue to experience such pressures, according to a new ... School of Medicine. Young women who recently experienced ...
... A new study from Hasbro Children,s Hospital finds visits ... team sports have increased dramatically over a 10-year period, ... football. The number of sports-related concussions is highest in ... is significant and rising. The study is published in ...
... Alan Mozes HealthDay Reporter , SUNDAY, Aug. ... low-dose omega-3 fatty acid supplements don,t appear to gain ... research cautions. In fact, neither low doses of ... found in fish oil, nor of alpha-linolenic acid (ALA), ...
... Dr. Hernn Makse, professor of physics at The City College ... way that information and infectious diseases proliferate across complex networks. ... contrary to conventional wisdom, persons with the most connections are ... where someone is located in a network," said Professor Makse ...
... Austin,s new Health Information Technology program has received $2.7 ... and Education for Health Information Technology (PURE HIT) consortium ... of Health and Human Services Office of the National ... graduated its first class of 54 students this summer. ...
Cached Medicine News:Health News:Multiple Sclerosis Changes With the Seasons 2Health News:Multiple Sclerosis Changes With the Seasons 3Health News:Study finds asking about pregnancy coercion and intimate-partner violence can reduce their incidence 2Health News:Study finds asking about pregnancy coercion and intimate-partner violence can reduce their incidence 3Health News:Concussions in young athletes on the rise 2Health News:Concussions in young athletes on the rise 3Health News:Low-Dose Omega-3 Fatty Acids Don't Protect Heart Patients 2Health News:Low-Dose Omega-3 Fatty Acids Don't Protect Heart Patients 3Health News:Location determines social network influence, CCNY-led team finds 2Health News:Location determines social network influence, CCNY-led team finds 3Health News:Health IT program at the University of Texas at Austin receives $2.7 million in federal funding 2Health News:Health IT program at the University of Texas at Austin receives $2.7 million in federal funding 3
...
...
Conforms to the convexity of the lens providing easier access to anterior capsule. Reduces pontential of corneal touch. 25G x 5/8in (.50 x 16mm)...
... Unique product designed for LASIK surgery ... Designed to irrigate the corneal interface ... easy insertion under the flap and ... ports provide multi-directional irrigation. Two 25G ...
Medicine Products: